The Possible Protective Effect of Marital Status in Quality of Life Among Elders in a U.S.-Mexico Border City.

Community Ment Health J

Universidad Autónoma de Ciudad Juárez, Av. Plutarco Elías Calles 1210, Juárez, 32310, Chihuahua, México.

Published: May 2018

The purpose of this study was to determine how marital status may have an impact on quality of life in a group of older adults living in a U.S.-Mexico border city. Two-hundred and seventy-six older adults completed the Spanish version of the World Health Organization Quality of Life Assessment, composed of four domains: physical health, psychological health, social relationships, and environment. Participants answered a measure of sociodemographic variables. In the psychological health component of quality of life, single and married older adults had the highest scores as compared to widowed and divorced. Similarly, married older adults had the highest quality of life in social relationships. Marital status may play an important role when analyzing quality of life among older adults, this study suggests that being married may offer a protective mechanism against depressive symptoms and therefore against mental illnesses during late adulthood.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910460PMC
http://dx.doi.org/10.1007/s10597-017-0166-zDOI Listing

Publication Analysis

Top Keywords

quality life
24
older adults
20
marital status
12
us-mexico border
8
border city
8
psychological health
8
social relationships
8
married older
8
adults highest
8
quality
6

Similar Publications

This study examined the effect of lymphedema self-care patient school education on patient functionality, quality of life, body value, and lymphedema volume in patients with lower extremity lymphedema. The study utilized a single-group quasi-experimental design. The study sample included 21 patients with primary and secondary lower extremity lymphedema.

View Article and Find Full Text PDF

Access to trained lymphedema care providers remains limited making patient-driven management solutions essential. One such option, sequential intermittent pneumatic compression (IPC), has gained traction as a supportive tool for lymphedema management. While newer IPC devices and innovative applications are being introduced to the market, questions regarding the safety and efficacy of this technology persist.

View Article and Find Full Text PDF

Background: In patients with post-thrombotic syndrome (PTS), stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial tested whether daily aspirin 100 mg plus rivaroxaban 20 mg is superior to rivaroxaban 20 mg alone to prevent stent thrombosis within 6 months after stent placement for PTS.

View Article and Find Full Text PDF

Introduction: Breast cancer is the most prevalent cancer among women worldwide, and advancements in detection and treatment have improved survival rates. Evaluating breast cancer patients' quality of life is essential for effective healthcare planning. This study aims to assess the level of quality of life and its associated factors, including sociodemographic, clinical, coping skills, and psychological factors among breast cancer women in Iraq.

View Article and Find Full Text PDF

Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.

Paediatr Drugs

January 2025

Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.

Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!